Moderna tried to assuage investors Thursday that enhanced scrutiny of its vaccines in the US wouldn’t hamper its progress.

Zocdoc launches AI phone assistant 'Zo' for scheduling medical appointments, with CEO Oliver Kharraz saying it's a natural ...

Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize ...

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...